AstraZeneca's sonesitatug vedotin gets FDA priority review for advanced gastric cancers
AZN•The FDA granted priority review to AstraZeneca's sonesitatug vedotin for certain advanced gastric and gastroesophageal cancers, with a decision expected in the second quarter of 2027. A Phase III trial showed a 42% reduction in the risk of death versus investigator's choice of therapy.




